Volastra Therapeutics is a biotechnology company that develops therapeutics targeting chromosomal instability in cancer. It offers small molecule inhibitors of KIF18A, including VLS-1488 in Phase I/II trials for tumors such as ovarian cancer, and sovilnesib in Phase Ib trials for platinum-resistant high-grade serous ovarian cancer and other TP53-mutated tumors. The company is active in the development of oncology drugs for solid tumor indications.